Momoko Okuda
Overview
Explore the profile of Momoko Okuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, et al.
J Thromb Haemost
. 2023 Nov;
22(2):430-440.
PMID: 37940048
Background: Emicizumab, a factor (F) VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment option for people with hemophilia A (PwHA). However, a small proportion...
2.
Iwata Y, Katada H, Okuda M, Doi Y, Ching T, Harada A, et al.
J Toxicol Sci
. 2023 Jul;
48(7):399-409.
PMID: 37394653
Fc-engineering is commonly used to improve the therapeutic potency of antibody (Ab) treatments. Because FcγRIIb is the only inhibitory FcγR that contains an immunoreceptor tyrosine-based inhibition motif (ITIM), Fc-engineered Abs...
3.
Muramatsu H, Kuramochi T, Katada H, Ueyama A, Ruike Y, Ohmine K, et al.
Sci Rep
. 2021 Jan;
11(1):2160.
PMID: 33495503
Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength....
4.
Konno H, Watanabe-Nakayama T, Uchihashi T, Okuda M, Zhu L, Kodera N, et al.
Proc Natl Acad Sci U S A
. 2020 Mar;
117(14):7831-7836.
PMID: 32213585
The yeast prion protein Sup35, which contains intrinsically disordered regions, forms amyloid fibrils responsible for a prion phenotype []. Using high-speed atomic force microscopy (HS-AFM), we directly visualized the prion...
5.
Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, et al.
Neuropsychiatr Dis Treat
. 2017 Jan;
13:117-125.
PMID: 28123299
Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5-20...
6.
Kishi T, Matsuda Y, Mukai T, Matsunaga S, Yasue I, Fujita K, et al.
Compr Psychiatry
. 2015 Mar;
59:91-7.
PMID: 25724075
We conducted a cross-sectional survey to assess the prevalence of physical pain in Japanese major depressive disorder (MDD) and schizophrenia (SZ) patients as well as in healthy controls (HCs). We...
7.
Okuda M, Niwa T, Taguchi H
J Biol Chem
. 2015 Jan;
290(12):7833-40.
PMID: 25635051
Hsp104 solubilizes protein aggregates in cooperation with Hsp70/40. Although the framework of the disaggregase function has been elucidated, the actual process of aggregate solubilization by Hsp104-Hsp70/40 remains poorly understood. Here...
8.
Odani W, Urata K, Okuda M, Okuma S, Koyama H, Pack C, et al.
FEBS J
. 2014 Nov;
282(3):477-90.
PMID: 25406629
Amyloids are ordered protein aggregates composed of cross-β sheet structures. Amyloids include prions, defined as infectious proteins, which are responsible for mammalian transmissible spongiform encephalopathies, and fungal prions. Although the...